Microbot Medical Inc(MBOT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.26 | Insider Own | 9.14% | Shs Outstand | 67.2M | Perf Week | 11.92% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | -4.92% | Insider Trans | - | Shs Float | 61.0M | Perf Month | -9.17% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.08 | Inst Own | 17.33% | Short Float | 9.81% | Perf Quarter | -38.42% |
| Income | -0.02B | P/S | 209.16 | EPS this Y | -5.17% | Inst Trans | -19.62% | Short Ratio | 8.56 | Perf Half Y | -48.1% |
| Sales | 0.00B | P/B | 1.06 | EPS next 5Y | 8.8% | ROA | -30.68% | Short Interest | 5.99M | Perf YTD | -45.5% |
| Book/sh | 1.03 | P/C | 1.07 | EPS past 3/5Y | 45.91% 25.94% | ROE | -32.91% | 52W High | -61.82% ($2.86) | Perf Year | -49.54% |
| Cash/sh | 1.02 | P/FCF | - | Sales past 3/5Y | - | ROIC | -23.52% | 52W Low | 17.2% ($0.93) | Perf 3Y | -3.54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 53.95% | Gross Margin | -198.84% | Volatility(W/M) | 7.82% 6.46% | Perf 5Y | -84.92% |
| Dividend TTM | - | EV/Sales | 16.3 | Sales Y/Y TTM | - | Oper. Margin | -5348.84% | ATR (14) | 0.07 | Perf 10Y | -99% |
| Dividend Ex-Date | - | Quick Ratio | 17.82 | EPS Q/Q | 12.62% | Profit Margin | -4722.25% | RSI (14) | 48.52 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.56 | Sales Q/Q | - | SMA20 | 6.81% ($1.02) | Beta | 1.06 | Target Price | $5.38 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/08/18 | SMA50 | -12.59% ($1.25) | Rel Volume | 1.91 | Prev Close | $1.12 |
| Employees | 43 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -8.84% - | SMA200 | -40.98% ($1.85) | Avg Volume(3M) | 0.70M | Price | $1.09 |
| IPO | 1992/3/25 | Option/Short | Yes/Yes | Trades | 2770 | Volume | 1,334,965 | Change | -2.68% |
🩺 Microbot Medical (MBOT) is a healthcare company developing medical devices that leverage ultra-small robotic technology. The company is researching robotic-based platforms in the fields of intravascular procedures and minimally invasive surgery, with the goal of improving procedural precision and safety for clinicians. Given its clinical-stage nature, product commercialization and progress on regulatory approvals serve as key variables in determining the company's value.
Over the past 1 year, on the lower side
62% below its 1-year high.
Traded more than usual. That is 191% of its average volume.
MBOT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -5.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $20,916. Peers typically go for $143.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -84.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 17.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #91 of 142 in the industry
Based on market cap of $73M.
HYPR#89 Hyperfine Inc $76M PER - 
OM#90 Outset Medical Inc $76M PER - MBOT#91 Microbot Medical Inc $73M PER - 
LNSR#92 LENSAR Inc $72M PER - 
ECOR#93 ElectroCore Inc $68M PER - 
FAQ
What kind of company is MBOT?
MBOT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of MBOT?
The market cap of MBOT is approximately $73M, ranking 4,660 within its sector.
What is the 52-week high and low for MBOT?
MBOT has recorded a 52-week high of $2.86 and a low of $0.93.
